Syon Capital LLC Has $244,000 Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Syon Capital LLC lessened its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 22.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,072 shares of the biotechnology company’s stock after selling 6,254 shares during the quarter. Syon Capital LLC’s holdings in Grifols were worth $244,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. QRG Capital Management Inc. raised its holdings in Grifols by 5.9% in the 4th quarter. QRG Capital Management Inc. now owns 35,116 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 1,964 shares in the last quarter. Cardinal Capital Management raised its holdings in Grifols by 10.4% in the 4th quarter. Cardinal Capital Management now owns 93,616 shares of the biotechnology company’s stock valued at $1,082,000 after acquiring an additional 8,789 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Grifols by 350.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,111 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 10,979 shares in the last quarter. Morningstar Investment Services LLC acquired a new position in Grifols in the 4th quarter valued at approximately $186,000. Finally, BNP Paribas Financial Markets raised its holdings in Grifols by 20.0% in the 4th quarter. BNP Paribas Financial Markets now owns 138,915 shares of the biotechnology company’s stock valued at $1,606,000 after acquiring an additional 23,122 shares in the last quarter.

Grifols Stock Performance

Grifols stock opened at $7.02 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.29 and a current ratio of 2.79. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15. The business has a 50 day simple moving average of $6.97 and a 200 day simple moving average of $7.86.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft downgraded Grifols from a “hold” rating to a “sell” rating in a research report on Tuesday, March 12th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.